Skip to main
GRI

GRI Stock Forecast & Price Target

GRI Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

GRI Bio is a highly promising clinical-stage biotech company with two potential blockbuster drugs in the pipeline - GRI-0621 and GRI-0803. The company's recent Q1 financial results were in line with expectations, and further data and analysis have confirmed the positive top-line data for GRI-0621. With a large market potential for the treatment of idiopathic pulmonary fibrosis and other autoimmune disorders, the company's current valuation is attractive and offers significant upside potential for investors, despite the inherent risks involved in drug development.

Bears say

GRI Bio is a clinical-stage biotech company with a negative outlook due to potential balance sheet risks, uncertainty around product safety and efficacy, and the competitive nature of the biotech market. While the company recently reported positive top-line data for its IPF drug candidate, it has yet to generate revenue and may face challenges in commercializing its products and obtaining suitable reimbursement. The company's multiple reverse stock splits in recent years also highlight potential instability in its share price. Furthermore, macroeconomic factors and changing healthcare priorities may also impact investor sentiment towards biotech stocks, adding to the risks for GRI Bio.

GRI has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of GRI Bio Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About GRI Bio Inc (GRI) Forecast

Analysts have given GRI a Strong Buy based on their latest research and market trends.

According to 1 analysts, GRI has a Strong Buy consensus rating as of Jun 29, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $32, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $32, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

GRI Bio Inc (GRI)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.